Skip to content
  • [email protected]
Facebook Linkedin Instagram
Donate
  • Home
  • About us
    • Who we are
    • Meet our team
    • Medical Advisory Committee
    • Our Advocacy
    • Contact Us
  • About Cardiomyopathy
    • What is Cardiomyopathy
    • Newly Diagnosed
    • Types of Cardiomyopathy
      • Arrhythmogenic Cardiomyopathy (ACM)
      • Amyloid Cardiomyopathy
      • Dilated Cardiomyopathy (DCM)
      • Hypertrophic Cardiomyopathy (HCM)
      • Left Ventricular Non-Compaction (LVNC)
      • Peripartum Cardiomyopathy (PPCM)
      • Restrictive Cardiomyopathy (RCM)
      • Takotsubo cardiomyopathy
  • Support & Resources
    • Information Sheets
    • How We Can Support You
    • Young People, Families, and Carers
    • Emotional Wellbeing
    • Community Voices
    • Knowledge Hub
    • Genetic Testing
  • Research & Trials
    • Research Opportunities
  • News & Events
  • Support us
  • Home
  • About us
    • Who we are
    • Meet our team
    • Medical Advisory Committee
    • Our Advocacy
    • Contact Us
  • About Cardiomyopathy
    • What is Cardiomyopathy
    • Newly Diagnosed
    • Types of Cardiomyopathy
      • Arrhythmogenic Cardiomyopathy (ACM)
      • Amyloid Cardiomyopathy
      • Dilated Cardiomyopathy (DCM)
      • Hypertrophic Cardiomyopathy (HCM)
      • Left Ventricular Non-Compaction (LVNC)
      • Peripartum Cardiomyopathy (PPCM)
      • Restrictive Cardiomyopathy (RCM)
      • Takotsubo cardiomyopathy
  • Support & Resources
    • Information Sheets
    • How We Can Support You
    • Young People, Families, and Carers
    • Emotional Wellbeing
    • Community Voices
    • Knowledge Hub
    • Genetic Testing
  • Research & Trials
    • Research Opportunities
  • News & Events
  • Support us

AHA 2023 Treatment Strategies for Cardiomyopathy in Children

Diagnosis and management considerations in paediatric cardiomyopathy. AHA 2023 Treatment Strategies for Cardiomyopathy in Children

2024 International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates

2024 International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates

EMQN: Recommendations for genetic testing in inherited cardiomyopathies and arrhythmias

2023 framework for genetic counselling and testing in inherited cardiovascular diseases. EMQN: Recommendations for genetic testing in inherited cardiomyopathies and arrhythmias

Heart Foundation of Australia: Additional resources to support patients with heart failure

Heart Foundation of Australia: Additional resources to support patients with heart failure Developed based on the Guidelines for the prevention, detection, and management of heart failure in Australia (the Guidelines), tools and resources to support provision of best practice care for patients with heart failure

Heart Foundation of Australia / Cardiac Society of Australia and New Zealand (CSANZ) Clinical Guidelines for the Diagnosis and Management of Heart Failure (2018)

Nationally endorsed guideline aligning with Australian practice, referral pathways, and available therapies. Heart Foundation of Australia / Cardiac Society of Australia and New Zealand (CSANZ) Clinical Guidelines for the Diagnosis and Management of Heart Failure (2018) 

ESC 2021 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

European counterpart addressing diagnostic algorithms, imaging, comorbidities, and management of heart failure with reduced and preserved ejection fraction. ESC 2021 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 

ACC / AHA / HFSA 2022 Guideline for the Management of Heart Failure

Comprehensive guidance on diagnosis, classification, and management of heart failure, including updated pharmacological therapy (ARNI, SGLT2 inhibitors), devices, and advanced care. ACC / AHA / HFSA 2022 Guideline for the Management of Heart Failure   

ESC Peripartum Cardiomyopathy Position Statement (2020)

Diagnosis, management, and counselling for future pregnancies. ESC Peripartum Cardiomyopathy Position Statement (2020)

AHA / ACC 2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Updates the 2020 guideline with revised diagnostic criteria, risk stratification, and management including new pharmacological therapies and genetic counselling guidance. AHA / ACC 2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis (2024)

Regionally tailored recommendations on investigation, diagnosis, and management of cardiac amyloidosis, incorporating local service structures and therapy access.  Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis (2024)   

Next →

You are welcome here. Kia Ora.

CMANZ is for everyone in the cardiomyopathy community. Whether you have been diagnosed yourself, are a family member or loved one of someone with cardiomyopathy, or have a professional interest, we are here to assist.  We welcome those of any age, gender, sexuality, culture, religion, and ability.

Cardiomyopathy Australia New Zealand would like to acknowledge the traditional custodians of the lands where we live, learn, and work and pay respect to Elders past and present.

quick links

Home
Who we are
What is Cardiomyopathy?
How We Can Support You
Research Opportunities
Support us

Contact Info

  • [email protected]
  • 22/113 Poinciana Ave, Tewantin, QLD 4565, Australia

    ABN: 091 171 470

join our Newsletter

Stay up to date with news, events and support for living with cardiomyopathy.

Sign up

Copyright 2026 by CMANZ | All rights reserved | Privacy Policy | Terms of use |  Blick Creative

Facebook X-twitter Linkedin